A biotech company is building lab-grown models of scar tissue in the back of the eye to test drugs for a blinding disease that currently has no treatment. This matters because age-related macular degeneration (AMD) affects 200 million people globally, and up to 70% of them develop subretinal fibrosis—a build-up of scar tissue beneath the retina that destroys light-sensitive cells and causes irreversible vision loss. No existing drug stops or reverses this scarring. Pharmaceutical companies lack reliable preclinical tools to screen potential treatments, so promising compounds often fail in human trials after costly animal studies. If MediNect’s models work, drug developers could test therapies faster and more accurately without relying on live animals. The company starts with simple 2D cell cultures that mimic fibrotic damage, then moves to 3D tissue models that replicate the retina’s structure. The ultimate goal is a fully functional 3D retinal model that could replace animal testing entirely. Success would give pharmaceutical companies a standardised platform to screen compounds, optimise drug delivery, and study how fibrosis progresses—potentially accelerating the development of the first effective treatment for this blinding complication of AMD.
View original technical description
MediNect Bioservices is advancing the frontiers of preclinical research in ophthalmology by expanding its capabilities to address critical unmet needs in retinal disease. Our main innovation is an in vivo model of subretinal fibrosis, a devastating end-stage phenotype of age-related macular degeneration (AMD) that leads to irreversible vision loss. Subretinal fibrosis is a significant challenge in AMD, with no effective treatments currently available. Existing therapeutic strategies fail to address the fibrotic processes that underlie the progression of this condition, leaving patients with limited options and a severe decline in quality of life. To tackle this, MediNect is building a comprehensive preclinical offering that combines cutting-edge in vivo and in vitro models to evaluate new therapies for retinal fibrosis. In line with the principles of the 3Rs (Replace, Reduce, Refine), we aim to significantly reduce reliance on animal testing while enhancing the scientific rigour and translational value of our research. Our approach begins with robust 2D in vitro models that replicate cellular fibrotic damage, progressing to advanced 3D tissue models that replicate the complexity of the retinal environment. These models will provide pharmaceutical developers with invaluable tools to screen compounds, optimise therapeutic delivery, and study disease mechanisms in detail that is currently not offered in the industry. Ultimately, our goal is to develop a fully functional 3D model of retinal disease, which could eliminate the need for animal models altogether, while offering insights into disease progression and treatment efficacy. The market need for preclinical solutions in ophthalmology is valued at $800M (Grand View Research, 2023). AMD affects 200 million patients globally (Bright Focus, 2022), with up to 70% of patients developing subretinal fibrosis an endpoint that significantly contributes to blindness and healthcare burden. Developing effective treatments for this condition requires predictive and translationally relevant preclinical models, which MediNect is uniquely positioned to deliver. Through this initiative, MediNect aims to cement its position as a world-leading preclinical research organisation specialising in ophthalmology. The funding will enable us to expand our capabilities, accelerate innovation, and provide pharmaceutical companies with transformative tools to develop effective therapies for retinal diseases. This project not only supports the growth of MediNect but also addresses a pressing global health need, paving the way for better treatments and improved patient outcomes in retinal disease.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know